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A B S T R A C T
Background
Invasive urodynamic tests are used to investigate men with lower urinary tract symptoms (LUTS) and voiding dysfunction to determine
a definitive objective diagnosis. The aim is to help clinicians select the treatment that is most likely to be successful. These investigations
are invasive and time-consuming.
Objectives
To determine whether performing invasive urodynamic investigation, as opposed to other methods of diagnosis such as non-invasive
urodynamics or clinical history and examination alone, reduces the number of men with continuing symptoms of voiding dysfunction.
This goal will be achieved by critically appraising and summarising current evidence from randomised controlled trials related to clinical
outcomes and cost-effectiveness. This review is not intended to consider whether urodynamic tests are reliable for making clinical
diagnoses, nor whether one type of urodynamic test is better than another for this purpose.
The following comparisons were made.
• Urodynamics versus clinical management.
• One type of urodynamics versus another.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, issue 10), MEDLINE (1 January 1946 to Week
4 October 2014), MEDLINE In-Process and other non-indexed citations (covering 27 November 2014; all searched on 28 November
2014), EMBASE Classic and EMBASE (1 January 2010 to Week 47 2014, searched on 28 November 2014), ClinicalTrials.gov and
the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (searched on 1 December 2014 and 3
December 2014, respectively), as well as the reference lists of relevant articles.
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Selection criteria
Randomised and quasi-randomised trials comparing clinical outcomes in men who were and were not investigated with the use of
invasive urodynamics, or comparing one type of urodynamics against another, were included. Trials were excluded if they did not report
clinical outcomes.
Data collection and analysis
Three review authors independently assessed trial quality and extracted data.
Main results
We included two trials, but data were available for only 339 men in one trial, of whom 188 underwent invasive urodynamic studies.
We found evidence of risk of bias, such as lack of outcome information for 24 men in one arm of the trial.
Statistically significant evidence suggests that the tests did change clinical decision making. Men in the invasive urodynamics arm were
more likely to have their management changed than men in the control arm (proportion with change in management 24/188 (13%)
vs 0/151 (0%), risk ratio (RR) 39.41, 95% confidence interval (CI) 2.42 to 642.74). However, the quality of the evidence was low.
Low-quality evidence indicates that men in the invasive urodynamics group were less likely to undergo surgery as treatment for voiding
LUTS (164/188 (87%) vs 151/151 (100%), RR 0.87, 95% CI 0.83 to 0.92).
Investigators observed no difference in urine flow rates before and after surgery for LUTS (mean percentage increase in urine flow
rate, 140% in invasive urodynamic group vs 149% in immediate surgery group, P value = 0.13). Similarly, they found no differences
between groups with regards to International Prostate Symptom Score (IPSS) (mean percentage decrease in IPSS score, 58% in invasive
urodynamics group vs 59% in immediate surgery group, P value = 0.22).
No evidence was available to demonstrate whether differences in management equated to improved health outcomes, such as relief of
symptoms of voiding dysfunction or improved quality of life.
No evidence from randomised trials revealed the adverse effects associated with invasive urodynamic studies.
Authors’ conclusions
Although invasive urodynamic testing did change clinical decision making, we found no evidence to demonstrate whether this led
to reduced symptoms of voiding dysfunction after treatment. Larger definitive trials of better quality are needed, in which men are
randomly allocated to management based on invasive urodynamic findings or to management based on findings obtained by other
diagnostic means. This research will show whether performance of invasive urodynamics results in reduced symptoms of voiding
dysfunction after treatment.
P L A I N L A N G U A G E S U M M A R Y
Invasive urodynamic studies for the management of lower urinary tract symptoms (LUTS) in men with voiding dysfunction
Background on the condition
Voiding symptoms - one specific group of lower urinary tract symptoms - are those experienced by men who have difficulty passing
urine. Voiding symptoms may include a slow stream of urine, spraying of urine, difficulty in beginning urination and dribbling of
urine once the man believes he has finished. These symptoms can be extremely embarrassing and distressing for affected individuals
and may dictate or restrict how they live their lives.
Invasive urodynamic tests are used to measure nerve and muscle function, pressure around and in the bladder and other factors that
might help to explain why a man may experience these symptoms. Some men find these tests embarrassing or uncomfortable. However,
results might reveal the cause of the voiding symptoms, thereby guiding healthcare providers in choosing the most effective treatment.
This approach might lead to improvement in the relative success of these treatments and reduce the risk of harm from unnecessary
treatment.
Main findings of this review
We found two trials, which included around 350 men, although information was available for only 339 men in one trial. Evidence was
not sufficient to show whether invasive urodynamic tests led to better patient outcomes. Some evidence suggests that these tests did
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alter management decisions, resulting in fewer men undergoing surgery. No evidence indicates whether this change in management
led to fewer symptoms in men after treatment, and it is not known whether patients reported a better quality of life.
Adverse effects
No information obtained from the included trials reveals how common side effects were in those undergoing invasive urodynamic
testing.
Limitations of the review
Not enough information from trials is available regarding the benefits of invasive urodynamic testing for men with voiding dysfunction.
More research is needed in which people are randomly assigned to treatment decisions based on their symptoms, physical examination
findings and results of non-invasive tests alone, or based on the extra information provided by invasive urodynamic tests. Future studies
will help healthcare providers determine whether patients benefit from these extra tests, and whether the tests provide good value for
healthcare systems.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: patients with lower urinary tract symptoms
Settings: hospital
Intervention: invasive urodynamic studies
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Invasive urodynamic
studies
Number treated with
surgery
1000 per 1000 870 per 1000
(830 to 920)
RR 0.87
(0.83 to 0.92)
339
(1 study)
⊕⊕©©
Lowa,b
Number whose treat-
ment was changed after
assessmentwith orwith-
out urodynamics
RR 39.41
(2.42 to 642.74)
339
(1 study)
⊕⊕©©
Lowa,b,c
Number of men with
continuing symptoms of
voiding dysfunction after
treatment following as-
sessment with and with-
out urodynamic studies -
not reported
See comment See comment Not estimable - See comment
Incidence of urinary
tract infection - not re-
ported
See comment See comment Not estimable - See comment
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Subjective participant
satisfaction with treat-
ment at 3 months after
treatment - not reported
See comment See comment Not estimable - See comment
Need for repeat or alter-
native treatment within 1
year - not reported
See comment See comment Not estimable - See comment
Health outcome mea-
sures such as quality-
adjusted life-years - not
reported
See comment See comment Not estimable - See comment
*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aAll domains of risk of bias assessment (except incomplete outcome data and selective reporting) were judged to be ‘ ‘ unclear’’ as
information was insufficient. Selective outcome reporting was judged to be at low risk of bias, whereas incomplete outcome data
were judged to be at high risk of bias.
bNot applicable, only 1 trial.
c95% confidence Interval was very wide (2.42 to 642.74). However, it did not cross the line of no effect.
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B A C K G R O U N D
Invasive urodynamic investigations may be performed in the diag-
nosis of lower urinary tract symptoms (LUTS) in men and in sub-
sequent planning and management. Urodynamic investigations
measure bladder pressure and urine flow rate during bladder filling
and voiding to assess the function of the lower urinary tract and
to identify the cause(s) of urinary storage or voiding symptoms.
In the evaluation of LUTS in men with voiding dysfunction, the
aim of urodynamic tests is to measure dysfunction while differ-
entiating between possible causes of symptoms, so that the most
likely effective method of treatment can be selected. For men with
voiding dysfunction, urodynamics is commonly used to detect
the presence of bladder outlet obstruction (BOO) and detrusor
underactivity (DU, or weak bladder contraction during voiding),
which give rise to similar clinical symptoms (Hosker 2009). Dis-
tinguishing between LUTS due to BOO and LUTS due to DU
is important, as this approach may influence management deci-
sions specifically related to surgery for BOO. Low-level evidence
suggests that making this distinction is important, as clinical out-
comesmay be affected (Hosker 2009). Detrusor overactivity (DO,
or inappropriate bladder contractions during storage) is a storage
phase problem that can be associated with urinary urgency symp-
toms. Prevalence of DO increases with age, and DO can be ob-
served as a feature of urodynamic tests in some men with voiding
dysfunction.
Description of the condition
Definitions and terminology
Lower urinary tract symptoms (LUTS)
Lower urinary tract symptomsmay be divided into three categories
depending on the phase of the micturition cycle affected.
• Storage symptoms, those experienced during the storage
phase, include increased daytime frequency, nocturia, urgency
and urinary incontinence (Abrams 2002).
• Voiding symptoms, those arising during the voiding phase
of the micturition cycle, include slow stream, splitting or
spraying, intermittency, hesitancy, straining and terminal dribble
(Abrams 2002).
• Postmicturition symptoms, those experienced immediately
after micturition, include a feeling of incomplete emptying and
postmicturition dribble (Abrams 2002).
Although most men report a combination of the above groups
of symptoms, this review focuses on investigation of voiding dys-
function inmen and therefore primarily assesses menwith voiding
and postmicturition symptoms. Storage symptoms are the main
focus of another Cochrane review (Clement 2013).
Voiding dysfunction
Voiding LUTS are experienced during the voiding phase (empty-
ing the bladder) of micturition (Abrams 2002). The voiding phase
of the micturition cycle alternates with the storage phase and is
under voluntary brain control, leading to both contraction of the
bladder wall and relaxation of the urethral sphincter. Voiding dys-
function is caused most commonly by poor contractility of the
bladder wall in DU, or by enlargement of the prostate gland in
benign prostatic hyperplasia (BPH), leading to BOO.
Voiding dysfunction in men may have many different causes; it
is important to differentiate between these causes to determine
appropriate management.
• Bladder outlet obstruction may be caused by anatomical or
functional problems. The most common cause is benign prostatic
enlargement (BPE), which compresses the urethral canal, leading
to obstruction of the normal flow of urine. Other anatomical
causes of BOO include bladder tumour, urethral stricture,
prostatitis and foreign body (Oelke 2013). Functional causes of
BOO include detrusor-sphincter dyssynergia - inappropriate
contraction of the internal urethral sphincter during voiding that
occurs as a consequence of neuronal injury such as injury to the
spinal cord. Other causes include primary bladder neck
obstruction and pelvic floor dysfunction (Dmochowski 2005).
Bladder outlet obstruction may be accompanied by DO.
• Detrusor underactivity is defined as “detrusor contraction
of reduced strength and/or duration, resulting in prolonged
bladder emptying and/or failure to achieve complete bladder
emptying within a normal time span” (Abrams 2002). It is
thought to be multi-factorial in origin. “Primary” or “idiopathic”
DU is thought to be due to the natural age-related decrease in
detrusor contractility. However, not everyone in this group will
become clinically symptomatic. Other causes of DU include
BOO (secondary to chronic overstretching of the detrusor
muscle, leading to muscle damage and hence an inability to
contract) and diabetes mellitus (van Koeveringe 2011).
VoidingLUTS inmen are a commonproblem. It has been reported
that among men 50 to 80 years of age, 90% suffer from voiding
LUTS at some point (NICE 2010). In one population-based study
in the USA, it was reported that 6% of all men (n = 2125) over
40 years of age had isolated voiding dysfunction as defined by the
International Prostate Symptom Score (IPSS). Nine percent of all
men had mixed voiding and storage LUTS (Glasser 2007). These
figures may not reflect the true scope of the problem, as men may
not present to a healthcare professional or admit that they are
troubled because of embarrassment. Alternatively, some men may
be affected but may not find these symptoms to be a problem.
Lower urinary tract symptoms inmen becomemore commonwith
increasing age. They are associated with obesity, diabetes mellitus
and a genetic susceptibility (Parsons 2010).
Overactive bladder syndrome
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Overactive bladder syndrome (OAB) is defined as “urgency, with
or without urge incontinence, usually with frequency and noc-
turia in the absence of an underlying metabolic or pathologic con-
dition.” Detrusor overactivity in the presence or absence of ur-
gency is defined as “a urodynamic observation characterised by
involuntary detrusor contractions during the filling phase which
may be spontaneous or provoked” (Abrams 2002). Although not
strictly a direct cause of voiding dysfunction, OAB is a major cause
of LUTS in men. Therefore if present, OAB symptoms or DO
on urodynamics may influence a clinician’s management plan for
concomitant BOO, for example, by altering the likelihood of pro-
ceeding to surgery or counselling the patient about the chance of
symptom resolution.
Description of the intervention
The term ’urodynamics’ is commonly used to refer to a wide va-
riety of physiological measurements of bladder and urethral func-
tion that aim to demonstrate a causal abnormality of storage and
voiding. The term may also be used to signify multi-channel cys-
tometry, but several tests, including non-invasive free flow rate
testing, can be described as urodynamic tests.
Cystometry is an invasive method of investigation. At aminimum,
a catheter must be inserted into the bladder. A range of measure-
ments can be taken, including urinary flow rate; pressure within
the urethra, bladder and abdomen; and electrical nerve recording
(Gorton 1999). A significant number of study participants have
reported that undergoing these investigations was embarrassing
and painful for them (Gorton 1999; Shaw 2000). Nevertheless,
cystometric studies have been invaluable in aiding our understand-
ing of the physiological and pathophysiological processes involved
in the development of voiding dysfunction (Chapple 2006).
When urodynamic studies are performed inmen, themost impor-
tant goal is to reproduce symptoms, so that the causes of symptoms
of voiding dysfunction and associated storage abnormalities can
be determined. This is normally achieved by asking the patient to
urinate into a container that is used to measure the volume and
rate of urine passed (uroflowmetry) and then measuring the vol-
ume of urine contained in the bladder after urination (postvoid
residual volume) by performing an external ultrasound scan of the
bladder or catheterisation.
Next, a urinary catheter is normally inserted to fill the bladder
with water, saline or contrast medium to allow controlled repro-
duction of symptoms. Bladder sensations during bladder filling
are reported by patients, including a sensation of filling, a desire
to void, urgency and a sense of discomfort or pain. Concurrently,
various pressure measurements are taken during the phases of the
micturition cycle by using fluid-filled lines connected to external
transducers, or ’microtip’ transducers, inserted into both the blad-
der and the abdominal cavity via the rectum. When the bladder is
deemed to be “full” (cystometric capacity), the patient is given per-
mission to void, so that urinary flow rates can be related to changes
in pressure during bladder emptying; this is termed a ’pressure-
flow study’. The main pressure measurements taken include:
• intravesical pressure (pressure within the bladder; Pves ); and
• abdominal pressure (pressure within the abdominal cavity,
normally measured using a rectal catheter; Pabd ).
Both of these measurements are needed to derive the detrusor
pressure (Pdet ), which is the difference between bladder and ab-
dominal pressures (Pves - Pabd ) and is computed throughout the
test. Variation in these pressure measurements during phases of
themicturition cycle facilitates the diagnosis of various conditions,
provided a high-quality study is achieved and everyday symptoms
of the patient are reproduced during the test.
Other types of urodynamics
Videourodynamics is anothermethodof assessing the function and
anatomy of the lower urinary tract by using synchronous x-ray or
ultrasound imaging of the bladder with multi-channel cystometry.
This live imaging of the bladder may be recorded for future review.
Ambulatory urodynamics involves using portable devices to carry
out multi-channel cystometry with natural bladder filling. This
allows patients to conduct their normal activities of daily living
while they are being urodynamically assessed.
Gas cystometry uses carbon dioxide as the medium for filling the
bladder during the study. This approach has been found to be
unreliable and is not now recommended (Homma 1999). Surface
electromyography may be used as an indirect measure of pelvic
floor and sphincter muscle contractility, but it is not commonly
used in clinical practice.
Risks of invasive urodynamic tests
The main risks of urodynamic testing are those associated with
the process of urethral catheterisation, such as dysuria (painful
urination) and urinary tract infection (UTI). A separate Cochrane
review addresses interventions to reduce the incidence of infection
(Foon 2012). Urodynamic tests require the use of sophisticated
machines and technical expertise, both of which have cost impli-
cations for the healthcare system. Men may find testing to be an
uncomfortable or embarrassing experience.
The reproducibility of cystometry as a diagnostic investigation
has been called into question (Kortmann 2000; Sonke 2000), as
have its specificity and sensitivity in differentiating between causes
of LUTS (Belal 2006). It has been suggested that the correlation
between urodynamic findings and symptoms in men with LUTS
may be poor (Eckhardt 2001).
How the intervention might work
The National Institute for Health and Care Excellence (NICE)
in the UK recommends that men contemplating surgery for the
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treatment of LUTS should be offered invasive urodynamic inves-
tigations (NICE 2010).
A Committee of the International Consultation on Incontinence
(ICI) in 2009 published an overview of the best scientific evi-
dence with regard to the role of cystometry in the treatment of
people with urinary incontinence or voiding difficulties (Hosker
2009). This overview reported that evidence demonstrating that
invasive urodynamics improves clinical outcomes in men investi-
gated for LUTS related to BOO and DO is limited; nonetheless
the ICI advised that the investigation should be performed be-
fore surgical intervention is provided (Hosker 2009). The research
behind these recommendations is conflicting. Some studies have
suggested that preoperative detection of DO facilitated the predic-
tion of postoperative complications such as incontinence (Aboseif
1994; Monoski 2006; Seki 2006). Other evidence supports the
contrary assertion that preoperative DO does not predict post-
prostatectomy incontinence (Golomb 1999; Kleinhans 1999).
One type of urodynamic investigation may provide more useful
information than another. This issue has been addressed by studies
comparing the utility of ambulatory urodynamics versus conven-
tional cystometry, particularly in determining the contribution of
detrusor overactivity to LUTS in men. In one study, conventional
urodynamics was compared with ambulatory urodynamics, and
ambulatory urodynamics was found to be more sensitive in de-
tecting DO; however, this finding was not correlated with a better
outcome (Robertson 1996).
Why it is important to do this review
The diagnostic accuracy of a test is normally determined by veri-
fying test results against a reference (’gold’) standard that defines
true disease status. The diagnostic performance of cystometry can-
not be assessed in this way, however, because no gold standard has
been accepted. In the absence of a gold standard, no alternative
may be available for evaluating whether the treatment response
after cystometry leads to improved health gains compared with
the treatment response after tests that do not include cystometry.
Furthermore, these tests are not provided without cost: They are
invasive and expensive and may produce adverse effects. For the
financial year 2011-2012, in the National Health Service (NHS)
in England, urodynamic testing for one patient on an outpatient
basis was calculated to cost £147. This cost increased to £340 on
a day-case basis. With regard to adverse effects, it is estimated that
cystometry results in a 3% or greater incidence of symptomatic
UTI (Foon 2012).
The value of accurate diagnosis depends on the availability and
effectiveness of appropriate treatments. Accurate diagnosis is of
no clinical value unless it is known, for example, that cystometry
can distinguish between a group for whom surgery is effective and
another group for whom it is neither effective nor contraindicated,
or for whom treatment needs to be altered in a specific way.
The value of invasive urodynamic investigation in the diagnosis
and management of men with LUTS associated with voiding dys-
function is therefore uncertain.
This review addresses whether the extra information generated by
invasive urodynamic testing influences clinical decision making
regarding management of voiding LUTS in men, and particularly
whether this leads to improvement in clinical and health economic
outcomes.
O B J E C T I V E S
To determine whether performing invasive urodynamic investi-
gation, as opposed to other methods of diagnosis such as non-
invasive urodynamics or clinical history and examination alone,
reduces the number of men with continuing symptoms of voiding
dysfunction. This goal will be achieved by critically appraising and
summarising current evidence from randomised controlled trials
related to clinical outcomes and cost-effectiveness. This review is
not intended to consider whether urodynamic tests are reliable for
making clinical diagnoses, nor whether one type of urodynamic
test is better than another for this purpose.
The following comparisons were made.
• Urodynamics versus clinical management.
• One type of urodynamics versus another.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We searched for all randomised or quasi-randomised controlled
trials on the management of voiding dysfunction in which men
with symptoms were randomly assigned to invasive urodynamic
testing in at least one arm of the study.
We excluded studies that did not report clinical outcomes of LUTS
management nor effects on clinical decision making.
Types of participants
Allmen with voiding LUTS presenting for investigation andman-
agement of their LUTS, as defined by the trial authors.
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Types of interventions
The intention was to answer the following clinical questions.
• Do invasive urodynamic investigations improve the clinical
outcomes of men with voiding dysfunction?
• Do invasive urodynamic investigations alter clinical
decision making?
• Is one type of invasive urodynamics better than another for
improving the outcomes of management of LUTS due to
voiding dysfunction and/or for influencing clinical decisions?
• Do invasive urodynamic tests identify risk factors for an
adverse outcome after surgery?
The intention was to perform the following comparisons.
• Invasive urodynamic tests versus clinical management
without invasive urodynamics.
• One type of urodynamic test versus another.
Because a reference (’gold’) standard investigation is not available
for comparison, this review does not aim to determine whether
invasive urodynamic studies are reliable for making a clinical diag-
nosis, nor whether one type of urodynamic investigation is better
than another for this purpose.
Interventions
We searched for invasive urodynamic investigations used as part
of a diagnostic workup before management decisions were made.
All types of urodynamics were eligible for consideration in this
review (AHCPR 1996; Homma 1999), including the following.
• Cystometry (simple, multi-channel or subtracted: study of
the pressure/volume relationship of the bladder during urine
storage (filling cystometry) and urine expulsion (voiding
cystometry)).
• Pressure-flow studies of voiding (study of the bladder
pressure/urine flow rate relationship during voiding).
• Urethral pressure measurements (profilometry:
measurement of pressure within the urethra; urethral closure
pressure is defined as the difference between intraluminal
pressure in the urethra and intravesical pressure in the bladder at
rest or during stress such as coughing or straining).
• Leak point pressure measurements (pressure within the
bladder at which leakage of urine from the urethra occurs: a
direct measure of the closure function of the entire urethra).
• Penile cuff test (non-invasive measurement of bladder
pressure during voiding, taken by providing intermittent
occlusion of the urinary stream with an inflatable cuff placed
around the penis).
• Electromyography (direct measurement of the contractility
of muscles concerned with continence, i.e. urethral sphincter,
anal sphincter or pelvic floor muscles).
• Videourodynamics (radiological (x-ray) imaging and
urodynamic measurements of the lower urinary tract performed
simultaneously during filling and voiding).
• Ambulatory urodynamic monitoring (urodynamic test
performed with natural bladder filling under circumstances in
which the patient’s mobility is minimally restricted).
Cystoscopy and imaging tests (radiography, ultrasonography) are
not usually considered routine urodynamic tests and were not
included in this review.
Although the specific management decisions made and the treat-
ments that patients undergo after assessment with or without uro-
dynamics are not included among the interventions assessed in
this review, it is important to note that it is the outcome of these
by which the usefulness of urodynamics is to be judged. There-
fore, to minimise bias associated with systematic differences in
care between centres or treatment modalities, we assessed included
studies for statements that diagnostic procedures and subsequent
interventions had been carried out according to an internationally
accepted standard. Furthermore, for trials in which a new inter-
vention was deployed, we sought statements regarding whether
training and learning curves were concluded before the start of the
trial.
Comparators
We included assessments that do not include invasive tests, such
as:
• clinical history;
• physical examination;
• symptoms reported by questionnaire;
• uroflowmetry and residual volume measurement; and
• bladder diaries.
Uroflowmetry and residual urine measurement (recording the vol-
ume of fluid expelled via the urethra per unit time during voiding,
and the volume of urine left in the bladder after voiding) can be
considered as part of urodynamic testing, but alone, they are not
by definition invasive and therefore were considered as a compara-
tor in this review unless they were performed in conjunction with
other invasive urodynamic tests. This allowed determination of
whether urodynamic studies as a whole, or mainly the uroflowme-
try and residual urine measurement (non-invasive) portions of the
study, influence decisions and outcomes.
Types of outcome measures
We selected outcome measures used in this review on the basis of
their relevance to the clinical cure or improvement of LUTS in
men with voiding dysfunction, or to management decisions made
to address this problem.We regarded the primary outcomes of this
review as clinical outcomes, as assessed by symptoms, question-
naire (e.g. IPSS) or urinary diary. In addition, we quantified the
influence of invasive urodynamic testing on clinical decisions. We
excluded studies that did not report clinical outcomes or effects
on clinical decision making.
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We adopted the recommendations provided by the Standardisa-
tion Committee of the International Continence Society for out-
comes of research investigating the effects of therapeutic inter-
ventions for people with voiding dysfunction or urinary incon-
tinence. These outcome categories include observations (symp-
toms) of people investigated for voiding dysfunction, quantifi-
cation of symptoms, the clinician’s observations (anatomical and
functional), quality of life and socioeconomic measures (Lose
1998).
Data could be obtained from history and questionnaire assess-
ment, or from urinary diaries (including frequency of micturition
and voided volumes).
The review also included adverse events as outcome measures.
The ideal minimum follow-up for our primary outcome and for
other relevant clinical outcomes is one year after urodynamics. We
analysed separately trials reporting follow-up periods of different
lengths for each outcome.
Primary outcomes
• Number of men with continuing symptoms of voiding
dysfunction after treatment following assessment with and
without urodynamic studies at least one year after assessment.
Secondary outcomes
Clinical decision making
• Number of men receiving conservative, drug or surgical
treatment.
• Number of men whose intended treatment was changed
after invasive urodynamics.
• Need for repeat or alternative treatment.
Participant observations
• Symptom scores (e.g. IPSS).
• Storage symptoms (urgency, increased daytime frequency,
nocturia).
• Urinary incontinence.
• Use of pads.
• Satisfaction with treatment.
• Time to return to normal activity.
Quantification of associated signs and symptoms
• Frequency of micturition as reported through the use of a
bladder diary.
• Nocturia.
• Urine flow rate.
• Voided volumes.
Clinician observations (anatomical and functional)
• Clinician-observed urinary incontinence.
• Need for further treatment.
Adverse effects
• Adverse events due to the method of investigation (e.g. UTI
after urodynamic investigation).
• Adverse events due to subsequent clinical management.
• Deaths.
Quality of life
• General health status measures (physical, psychological,
other).
• Condition-specific health measures (specific instruments
designed to assess the effects of voiding dysfunction on quality of
life).
• Psychological health status measures (e.g. Hospital Anxiety
and Depression Score (HADS)).
Economic outcomes
• Health economic measures.
• Costs of investigations.
• Costs of treatment and re-treatment.
Other outcomes
• Non-prespecified outcomes judged important while the
review was conducted.
Quality of evidence
We classified primary and secondary outcomes, as defined above,
as ’critical’, ’important’ or ’not important’ for decision making
from the participant’s perspective. The GRADE Working Group
strongly recommends including up to seven outcomes in a system-
atic review. In this systematic review, we adopted GRADE (Grad-
ing of Recommendations, Assessment, Development and Evalu-
ation) methodology to assess the quality of available evidence for
the following outcomes.
• Number treated with surgery.
• Number whose treatment was changed after assessment
with or without urodynamics.
• Number of men with continuing symptoms of voiding
dysfunction after treatment following assessment with and
without urodynamic studies.
• Incidence of UTI.
• Subjective participant satisfaction with treatment at three
months after treatment.
• Need for repeat or alternative treatment within one year.
• Health economic outcome measures such as quality-
adjusted life-years (QALYs).
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Search methods for identification of studies
We did not impose language, status of publication or other limits
on the searches described below, unless otherwise stated.
Electronic searches
We searched the following electronic bibliographic databases, all
on Ovid SP.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (2014, issue 10) on 28 November 2014 on Ovid
SP. The search strategy is given in Appendix 1.
• MEDLINE (1 January 1946 to October Week 4 2014) and
MEDLINE In-Process and other non-indexed citations
(covering 27 November 2014) (both searched on 28 November
2014). The search strategy is given in Appendix 2.
• EMBASE Classic and EMBASE (1 January 2010 to Week
47 2014, searched on 28 November 2014). Explanations for the
date limitation and the search strategy are given in Appendix 3.
We sought ongoing trials and trial results in the following trial
results registers and platforms. The search terms used are given in
Appendix 4.
• ClinicalTrials.gov (date of last search: 1 December 2014).
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (date of last search: 3
December 2014).
Search terms tested but rejected (as they did not lead to retrieval
of any relevant records during testing) are given in Appendix 5.
Searching other resources
We searched the reference lists of relevant articles.
Data collection and analysis
We excluded studies if they were not randomised or quasi-ran-
domised trials for men with voiding dysfunction. In addition, we
excluded studies that did not report clinical outcomes or effects
on clinical decision making. We listed excluded studies along with
details of the interventions compared and the reasons for their
exclusion.
Weprocessed includeddata as described in theCochraneHandbook
for Systematic Reviews of Interventions (Higgins 2011).
Selection of studies
Three review authors independently evaluated the reports of all
possibly eligible studies for methodological quality and appropri-
ateness for inclusion without prior consideration of the results.
We resolved disagreements by discussion. When these were not
resolved, arbitration would have rested with a fourth person.
Data extraction and management
At least two review authors extracted data independently and cross-
checked them by using a customised data collection form. When
data may have been collected but were not reported, we sought
clarification from the trialists. We processed included trial data by
using RevMan software, as described in theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2011). We contacted
authors of original reports to request extra information and data
if required.
Assessment of risk of bias in included studies
Each review author independently critically appraised and assessed
risk of bias, as described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). The following were as-
sessed and reported in Cochrane risk of bias tables.
• Was the allocation sequence adequately generated?
• Was allocation adequately concealed?
• Were outcome assessors adequately blinded to intervention
allocation?
• Were incomplete outcome data adequately addressed?
• Are reports of the study free of the suggestion of selective
outcome reporting (or, were all relevant outcomes adequately
reported)?
• Were full details of financial support and funding for the
trial provided?
• Was a sample size calculated before recruitment, and did
sample size reflect the required numbers needed to meet a
particular statistical power?
• Was ethical approval sought and received before the trial
was begun?
• Was full informed consent obtained from trial participants?
Studies were considered to be at low risk of bias if the method of
blinding was adequate, or if we judged that lack of blinding could
not have affected the results or could not be avoided. We assessed
each element as having low risk, high risk or unclear risk of bias
(the latter usually when no information was supplied).
In this review, we decided to exclude from the risk of bias assess-
ment performance bias as a domain of risk of bias assessment.
Blinding of participants undergoing urodynamic testing or of staff
carrying out the testing is not possible andwould have been judged
as introducing ’high risk’ across all trials.
Measures of treatment effect
For categorical outcomes, we related the numbers reporting an
outcome to the numbers at risk in each group to derive a summary
risk ratio (RR). For continuous variables, we would have used
means and standard deviations (SDs) to derive a mean difference
(MD) if outcomes were measured the same way between trials.
However, data for both urine flow rate and the IPSS questionnaire
were provided as a percentage change, and so it was not possible
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to present these outcomes in forest plot form. Any continuous
data that were the product of several different scales (e.g. scales
used to assess symptoms such as pain or quality of life) would
have been summarised as the standardised mean difference (SMD)
by using a fixed-effect model. We used a fixed-effect model for
calculation of all summary estimates and 95% confidence intervals
(CIs) exceptwhenheterogeneitywas significant. Itwas not possible
to undertake meta-analysis because of the lack of included trials;
however we presented data in forest plot form for ease of graphical
representation.
Unit of analysis issues
Wewould have analysed studies with non-standard design, such as
cross-over trials and cluster-randomised trials, as described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011). We would have analysed studies with multiple treatment
groups by treating each pair of arms as a separate comparison, as
appropriate. All studies in this review were of standard design and
were two-armed trials.
Dealing with missing data
We defined an intention-to-treat analysis as analysing all partici-
pants in their randomly assigned groups, whether or not they re-
ceived the allocated intervention. We included data as they were
reported by the trialists for each outcome and did not imputemiss-
ing values. However, we would carry out sensitivity analyses if a
differential dropout from the randomly assigned groups occurred,
or if systematic bias from missing data was suspected for another
reason.
Assessment of heterogeneity
We would have combined trial data only if no clinical heterogene-
ity was apparent. We would have investigated differences between
trials if significant heterogeneity was revealed by the Chi2 or the I2
statistic (Higgins 2003), or was obvious from visual inspection of
study results and data plots. Visual heterogeneity would be deemed
positive when the confidence intervals of studies did not overlap.
This would then be confirmed by formal statistical testing. We
regarded statistical heterogeneity as substantial if I2 was greater
than 50%, as reported by the Cochrane Handbook for Systematic
Reviews of Interventions to be the cross-over between moderate and
substantial heterogeneity, or if the P value (< 0.10) in the Chi2
test for heterogeneity was low. For those outcomes, we could have
used a random-effects model.
Assessment of reporting biases
It would have been possible to assess publication bias by using a
funnel plot if any meta-analysis had included 10 or more studies.
Data synthesis
We used fixed-effect analysis to carry out meta-analyses except
when we suspected significant heterogeneity, at which time we
could have used a random-effects model.
Subgroup analysis and investigation of heterogeneity
Weplanned to carry out subgroup analysis on the following groups
if the data had allowed.
• Men in the following age groups: younger than 50 years of
age, 50 to 80 years of age and older than 80 years of age.
• Men undergoing a primary versus a secondary investigation
after failed treatment.
• Men presenting with and without additional storage LUTS.
• Men in urinary retention (i.e. with a catheter in situ) or not.
• Men with different causes of voiding dysfunction (e.g. BPE,
other).
Sensitivity analysis
It would have been possible to carry out a sensitivity analysis based
on eligibility criteria, such as by including and excluding results
from abstract-only publications, if we had identified enough trials
(Deeks 2011).
R E S U L T S
Description of studies
We screened for this review a total of 5716 records, as produced
by the literature search. We retrieved the full text of nine studies
for further consideration. However, we excluded seven (see below)
because they did not randomly assign participants to at least one
type of urodynamic investigation or one method of performing a
urodynamic investigation.
Additionally we identified one ongoing trial, which is open to
recruitment in theUK (Drake 2014; seeCharacteristics of ongoing
studies).
The flow of literature through the assessment process is shown in
the PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) flow diagram (Figure 1).
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Figure 1. PRISMA study flow diagram.
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Included studies
We found two trials that met the inclusion criteria (De Lima 2003;
Kristjansson 1999). We approached the authors of these trials to
ask for further information, but we received no response. One trial
was reported only as a conference abstract and provided no useable
data (Kristjansson 1999).
We identified no trials that compared one method of urodynamics
versus another and also provided clinical outcome data.
We have provided further details in the Characteristics of included
studies table.
Methods
The two identified studies were two-arm randomised controlled
trials with a standard parallel-group design. These studies:
• provided final outcome evaluation at six months (De Lima
2003); and
• reported an unclear duration of follow-up, with sole
outcome evaluation detailing future management within an
undefined time period (Kristjansson 1999).
Participants
Participant types included:
• men presenting between March 1993 and March 2001 with
LUTS (De Lima 2003); and
• men with LUTS (Kristjansson 1999).
Subgroup analysis according to type of participant was not possi-
ble, as only one trial provided useable data, which did not specify
outcomes according to subgroups (De Lima 2003).
Interventions
In the one included trial that provided useable data (De Lima
2003), participants were randomly assigned to undergoing urody-
namic investigations or not before transurethral resection of the
prostate (TURP). The following types of urodynamics were used.
• Cystometry and pressure-flow studies (De Lima 2003).
• Pressure-flow urodynamics (Kristjansson 1999).
Comparator or control groups received the following.
• Immediate TURP (De Lima 2003).
• Treatment based on symptoms, history or clinical findings
only (Kristjansson 1999).
Outcomes
All outcomes considered in each trial are detailed in the table
Characteristics of included studies.
Excluded studies
Of the nine studies considered, seven were excluded because they
did not report clinical outcomes (i.e. effect of the trial on urinary
outcomes) nor effect on clinical decision making.
Further details are given in the table Characteristics of excluded
studies.
Risk of bias in included studies
One trial provided no useable data (Kristjansson 1999); therefore
the rest of this section excludes evaluation of this trial. Evidence
of high risk of bias was noted in the one remaining trial (De Lima
2003).
Figure 2 and Figure 3 provide a visual summary of the findings.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
The one included trial with useable data (De Lima 2003) failed
to adequately describe the method of sequence generation imple-
mented and therefore was deemed to be at unclear risk of bias.
Similarly, no information regarding the method of allocation con-
cealment was provided; therefore the trial was deemed to be at
unclear risk of bias in this domain also.
Incomplete outcome data
Data for outcomes for the pretreatment group include only partic-
ipants who underwent surgery, not the 24 participants who were
not operated on (who may have received some sort of treatment,
e.g. drugs). This meant that we were unable to assess the over-
all difference and effects of immediate surgery versus urodynam-
ics before surgery. For this reason, this trial (De Lima 2003) was
deemed to be at high risk of bias in this domain.
Selective reporting
A range of outcomes were reported in the trial (De Lima 2003);
therefore it was deemed to be at low risk of bias.
Other potential sources of bias
Details of financial support, an adequate sample size calculation
and information on medical ethics approval for the trial and in-
formed consent of participants were not reported in the trial (De
Lima 2003); therefore it was deemed to be at unclear risk of bias.
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Effects of interventions
See: Summary of findings for the main comparison Invasive
urodynamic studies for the management of lower urinary tract
symptoms (LUTS) in men with voiding dysfunction
Urodynamics versus clinical management without
urodynamics
The one included trial that provided useable data (De Lima 2003)
addressed this comparison. This trial included 339 men, of whom
188 were randomly assigned to a urodynamic intervention.
Primary outcome (symptoms of voiding dysfunction after
treatment)
No data were available for this outcome.
Secondary outcomes
Clinical decision making
Men in the urodynamic arm of one trial (De Lima 2003) were
more likely to have their treatment changed after undergoing inva-
sive urodynamic studies (proportion with change in management
24/188 (13%) vs 0/151 (0%), risk ratio (RR) 39.41, 95% confi-
dence interval (CI) 2.42 to 642.74; Analysis 1.3). The RR for this
outcome was derived using Review Manager 5.2, and although
it seems high, it is correct. Because any number divided by 0 is
infinity, and to work out the RR the equation is (24/188)/(0/151)
making the denominator zero, Review Manager has substituted a
number in the region of 0.48 to make the calculation work. This
results in an RR of 39.41.
Men in the clinical assessment alone group were more likely to
undergo surgery as treatment for LUTS (151/151 (100%) vs 164/
188 (87%), RR 0.87, 95% CI 0.83 to 0.92; Analysis 1.2).
Participant observations
No difference in IPSS score was noted between groups (mean
percentage decrease in IPSS score, 57.64% in invasive urodynamic
group vs 59.43% in immediate surgery group, P value = 0.22;
Analysis 1.5).
Quantification of associated sign and symptoms
No difference was observed in urine flow rate before and after
surgery for LUTS (mean percentage increase in urine flow rate,
140.43% in invasive urodynamic group vs 148.52% in immediate
surgery group, P value = 0.13; Analysis 1.4). No data on quanti-
fying storage LUTS or DO were available.
Clinician observations (anatomical and functional)
The number of men still obstructed six months after surgery in the
clinical assessment alone group (De Lima 2003) was statistically
significantly higher than the number in the group assessed by
invasive urodynamic studies (27/151 (18%) vs 16/164 (10%), RR
0.55, 95% CI 0.31 to 0.97; Analysis 1.1).
Adverse effects
No data for these outcomes were available.
Quality of life
No data for these outcomes were available.
Economic outcomes
No data for these outcomes were available.
One type of urodynamics versus another
We identified no trials that compared one method of urodynamics
versus another and also provided clinical outcome data.
D I S C U S S I O N
Summary of main results
We found evidence from a single trial to suggest that invasive uro-
dynamic studies changed the management of lower urinary tract
symptoms (LUTS) in men with voiding dysfunction (risk ratio
(RR) 39.41, 95% confidence interval (CI) 2.42 to 642.74). Men
receiving clinical assessment alone were more likely to undergo
surgery as treatment for LUTS (RR 0.87, 95% CI 0.83 to 0.92).
Men receiving clinical assessment alone were statistically signif-
icantly more likely to be obstructed at six months after surgery
than were those assessed using invasive urodynamic studies (RR
0.55, 95% CI 0.31 to 0.97), but this information was missing for
24 of 188 men in one arm. No differences were observed between
groups in percentage increase of urine flow rate before and after
intervention (140% vs 149%, P value = 0.13). Similarly, no dif-
ference was noted between groups in the decrease in IPSS score
before and after intervention (58% vs 59%, P value = 0.22).
No evidence differentiated between different groups of men with
LUTS (Subgroup analysis and investigation of heterogeneity). De-
spite the expected incidence of UTI after the procedure (Foon
2012), no data were available from the included randomised trials
reporting on whether or not any adverse effects occurred.
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Overall completeness and applicability of
evidence
We found only two eligible trials, and of these, one did not provide
useable data. The excluded studies were mainly non-randomised
studies, and the study that randomly assigned participants to two
different methods of performing invasive urodynamics reported
no clinical outcomes, possibly because it was not designed to assess
whether urodynamics should be used and was focused mainly on
the best method for carrying out the investigation.
The one included study (De Lima 2003) did not provide what
we considered to be important clinical outcomes. Primary out-
come data were not reported, and five out of seven prespecified
GRADE (Grading of Recommendations, Assessment, Develop-
ment and Evaluation) outcomes were not reported, as highlighted
in Summary of findings for the main comparison.
One large ongoing trial, which began participant recruitment in
2014 (Drake 2014), may produce robust, reliable evidence in the
future.
Quality of the evidence
The only trial with useable evidence was classed as having unclear
risk of bias in most domains (Figure 3). Evidence of sufficient
random sequence generation and allocation concealment was un-
clear. Furthermore, no data were provided for most outcomes for
24 of 188 participants in one arm of the trial. Five out of seven
GRADE-specific outcomes were reported (Summary of findings
for the main comparison).
Agreements and disagreements with other
studies or reviews
Recent reviews on the topic of urodynamics have identified the
lack of high-quality primary research confirming the clinical utility
of carrying out urodynamic investigations (Hosker 2009; NICE
2010). This current review appraised the limited evidence available
from one randomised controlled trial, but information gathered
regarding the situations in which urodynamic studies are useful
was not conclusive.
Some consensus statements and practice recommendations ad-
vocate the use of invasive urodynamic studies in cases in which
patients and clinicians are contemplating surgery as treatment
for LUTS (Hosker 2009; NICE 2010). Conversely, one review
(Chapple 2006) recommended a trial of drugs for both benign pro-
static hyperplasia (BPH) and overactive bladder syndrome (OAB)
in the first instance, with urodynamics reserved for resistant cases.
The value of urodynamic studies for the management of LUTS
in men with voiding dysfunction requires further evaluation by
randomised controlled trials, with reporting of relevant subjective,
objective and economic outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When men with LUTS and voiding dysfunction were assessed by
invasive urodynamic studies, they were found to be more likely to
have theirmanagement changed and less likely to undergo surgery.
This may have been result of the fact that urodynamics identified
no objectively measurable bladder outlet obstruction (BOO) as a
cause of symptoms in somemen.However, information was insuf-
ficient to demonstrate whether this led to differences in subjective
symptom questionnaire scores or objectively observed urine flow
rate in those undergoing invasive urodynamic studies. Further-
more, no evidence was available to show whether these differences
in management resulted in differences in health outcomes, such
as quality of life or economic outcomes after treatment, compared
with management of those who did not undergo invasive urody-
namic testing.
Implications for research
Evidence regarding the value and risks of invasive urodynamics
remains insufficient. Further trials are needed in all subgroups of
men with voiding dysfunction whose LUTS could be investigated
with urodynamics. In such trials, men would be randomly as-
signed to treatment based on invasive urodynamic investigations
rather than treatment based on clinical history and examination
and other non-invasive clinical evaluations such as flow rate test-
ing. Future trials should include all men for whom urodynamics
might be indicated to ensure that those considering surgery but
who decided not to proceed as a result of urodynamic findings
are not missed, and that those for whom surgery is not an option
are also evaluated. Furthermore, investigators should take into ac-
count the seven specified GRADE outcomes within this review to
perform a comprehensive analysis of those outcomes most impor-
tant to clinical practice, as well as validated health status measures
to conduct an assessment of the impact of urodynamic studies and
subsequent clinical management on quality of life.
No evidence was found regarding the implications of storage
LUTS and filling cystometry findings such as DO for decision
making in the management of voiding dysfunction. Further tri-
als are needed to address issues such as whether management of
voiding dysfunction can reduce the severity of storage LUTS, or
whether it is associated with worse outcomes after surgical man-
agement. If so, urodynamic studies might identify men who need
supplementary treatment.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
De Lima 2003
Methods Prospective randomised trial
Setting: Division of Urology, University of Campinas Medical Centre, Unicamp, Camp-
inas, São Paulo, Brazil
Participants 452 men were enrolled and 339 were randomly assigned (A, 151; B, 188)
Inclusion criteria: patients undergoing transurethral resection of the prostate (TURP),
those with International Prostate Symptom Score (IPSS) > 15, urinary flow < 10 mL/s
Exclusion criteria: patients exposed to drugs (such as alpha agonists, anticholinergics,
cholinergics, diuretic agents, oestrogens, androgens, antihypertensive medications or
other agents) within the previous 2 weeks. History or evidence of prostate cancer, pelvic
irradiation, urethral stricture, surgery for benign prostatic hyperplasia (BPH), neurogenic
bladder dysfunction, hydronephrosis or urinary tract infection within 3 months before
the study. Not obstructed or equivocal obstruction found on urodynamics
113 patients were excluded on the basis of initial exclusion criteria. After urodynamic
testing, a further 24 patients were excluded, as they were not obstructed or had equivocal
obstruction
Interventions A (n = 151), immediate TURP
B (n = 188), urodynamic studies before TURP
Outcomes Number of men undergoing surgery (number/total number): A, 151/151; B, 164/188
Number of men whose treatment was changed after invasive urodynamics (number/total
number): A, 0/151; B, 24/188
Symptom scores (IPPS): A, presurgery score = 21.78 +/- 3.40, postsurgery score = 8.87
+/- 3.27, % decrease = 59.43%. B, presurgery score = 21.99 +/- 3.05, postsurgery score
= 9.32 +/- 3.14, % decrease = 57.64%. P value = 0.22 for figures, 0.22 for %
Urine flow rate (mL/s): A, presurgery = 6.8 +/- 1.4, postsurgery = 17.0 +/- 2.1, % increase
= 148.52%. B, presurgery score = 6.9 +/- 1.3, postsurgery score = 16.6 +/- 2.2, % increase
= 140.43%. P value = 0.15 for figures, 0.13 for %
Number of men still obstructed at 6months post surgery as measured using urodynamics
(number/total number): A, 27/151, 17.8%; B, 16/164, 9.75%. P value = 0.03
Notes Data for outcomes for group B (pretreatment) include only participants who underwent
surgery, not the 24 participants who were not operated on after urodynamic assessment
(who may have had some sort of treatment, i.e. drugs); therefore cannot assess overall
difference and effect of immediate surgery versus urodynamics
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Patients were prospectively randomised’
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De Lima 2003 (Continued)
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Data for outcomes for group B (pretreat-
ment) include only participants who un-
derwent surgery, not the 24 participants
who were not operated on (who may have
had some sort of treatment, i.e. drugs);
therefore cannot assess overall difference
and effect of immediate surgery versus uro-
dynamics
Selective reporting (reporting bias) Low risk Range of outcomes reported
Financial support Unclear risk No information provided
Sample size calculation Unclear risk No information provided
Medical ethics approval Unclear risk No information provided
Informed consent Unclear risk No information provided
Kristjansson 1999
Methods Randomised controlled trials
Setting: Department of Urology, Linköping University, Sweden
Participants Menwith lower urinary tract symptoms (LUTS) and suspected bladder outlet obstruction
(BOO) due to prostatic enlargement
Pressure-flow studies in group A showed:
• 68% moderate to severe obstruction;
• 5% slight obstruction;
• 9% grey zone;
• 11% normal resistance; and
• 7% inconclusive or not done.
Interventions A (N?): pressure-flow urodynamics with standardised treatment options
B (N?): treatment decision directly without urodynamics (control)
Outcomes Number treated conservatively (non-invasive transurethral microwave therapy (TUMT)
, drugs): A, 11%; B, 24%
Number treated with expectancy: A, 22%; B, 3%
Number treated surgically: A, 67%; B, 73%
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Kristjansson 1999 (Continued)
Notes Number of men randomly assigned not given; therefore data cannot be used
Abstract format only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’Randomised between A and B’
Allocation concealment (selection bias) Unclear risk ’Randomised between A and B’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided
Selective reporting (reporting bias) High risk No numbers reported
Financial support Unclear risk No information provided
Sample size calculation Unclear risk No information provided
Medical ethics approval Unclear risk No information provided
Informed consent Unclear risk No information provided
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Boormans 2007 Not randomly assigned to undergo urodynamics or an alternative
Ding 1998 Non-randomised and no clinical outcomes reported
English 2012 Retrospective case review, non-randomised
Klingler 1996 Non-randomised and no clinical outcomes reported
Losco 2013 Non-randomised
Tanabe 2011 Retrospective analysis of outcomes, non-randomised
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(Continued)
Zhao 2006 Compares one type of urodynamics versus another, but no clinical outcomes reported
Characteristics of ongoing studies [ordered by study ID]
Drake 2014
Trial name or title Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for
diagnosis and management of bladder outlet obstruction in men
Methods Randomised controlled parallel-group trial
Participants Inclusion:
• Men over the age of 18 considering undergoing surgery as a treatment option for their bothersome
LUTS.
• Willing to be randomly assigned.
Exclusion:
• Unable to pass urine without a catheter (urinary retention).
• Have a relevant neurological disease.
• Undergoing active treatment, or on active surveillance, for prostate or bladder cancer.
• Have previously had prostate surgery.
• Not medically fit for surgery, or unable to complete outcome assessments.
• Do not consent to be randomly assigned.
Interventions A care pathway based on urodynamic tests with invasive multi-channel cystometry (“Invasive urodynamics”
active intervention arm) and a care pathway based on non-invasive tests (i.e. without multi-channel cystom-
etry) (“usual care” control arm)
Outcomes Primary outcome measure:
• Difference in lower urinary tract symptoms (LUTS) between the 2 arms at 18 months, measured by
the International Prostate Symptom Score (IPSS).
Secondary outcome measures:
• Surgery rate (the relative proportion of men in each group having surgery up to 18 months after
randomisation).
• Cost-effectiveness analyses from the perspectives of the NHS, Personal Social Services and patients.
Subsequent need for surgery will be recorded.
• Adverse events of testing and treatment (e.g. infection, urinary retention).
• Measures from the International Consultation on Incontinence Questionnaires (ICIQ) (Abrams et al.,
2006) will be used alongside IPSS, allowing sensitive and comprehensive assessment of LUTS severity/
bother, sexual function, quality of life and satisfaction with urodynamic testing. The following will be
measured at 6, 12 and 18 months:
◦ IPSS.
◦ ICIQ male LUTS (ICIQ-MLUTS).
◦ ICIQ sexual function in male LUTS (ICIQ-MLUTS-sex).
◦ ICIQ quality of life (ICIQ-QoL).
◦ ICIQ urodynamics satisfaction (ICIQ-UDS-S) will be administered at a single time point after
urodynamic testing for relevant patients.
• Maximum urinary flow rate (Qmax) at 18 months. For men in both arms undergoing surgery, an
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Drake 2014 (Continued)
additional Qmax measure at 4 months after operation will be used as a quality measure for surgery.
• EQ-5D-5L will be used to provide the quality of life weights used to calculate quality-adjusted life-
years (QALYs).
• Qualitative interviewing will explore user acceptability and influences on decisions made by
participating men and surgeons.
Starting date 01/10/2014; currently recruiting
Contact information marcus.drake@bui.ac.uk
Notes Current Controlled Trials ISRCTN56164274; assigned 08/04/2014
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D A T A A N D A N A L Y S E S
Comparison 1. Urodynamics vs clinical management
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of men still obstructed
at 6 months post surgery
(objective)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Number treated with surgery 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Number whose treatment was
changed after assessment with
or without urodynamics
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Urine flow rate (objective) Other data No numeric data
5 International Prostate Symptom
Score (IPSS)
Other data No numeric data
C O N T R I B U T I O N S O F A U T H O R S
All review authors contributed to the writing of this review.
D E C L A R A T I O N S O F I N T E R E S T
One of the authors of this review (MD) is the Chief Investigator of the ongoing trial UPSTREAM (Drake 2014).
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• The National Institute for Health Research (NIHR), UK.
The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Incontinence Review Group.
Disclaimer:
The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the NIHR, the NHS
or the Department of Health.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The following outcome was not specified in the protocol.
• Number of men still obstructed at six months post surgery (objective).
We assessed the quality of evidence of the following two additional outcomes, as they were also considered important for clinical
decision making for the patient.
• Number treated with surgery.
• Number whose treatment was changed after assessment with or without urodynamics.
We also extracted information about the following.
• Financial support.
• Sample size calculation.
• Medical ethics approval.
• Informed consent.
These domains were not specified in the protocol as part of risk of bias assessment. However, we believe that Information about financial
support, sample size calculation, medical ethics approval and informed consent is important and highlights various aspects of how the
trial was conducted.
28Invasive urodynamic studies for the management of lower urinary tract symptoms (LUTS) in men with voiding dysfunction (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
